Aeglea BioTherapeutics Inc.
| NASDAQ: AGLE | Healthcare / Biotechnology / USA |
| 8.04 | +0.0900 | +1.13% | Vol 33.10K | 1Y Perf 47.76% |
| Apr 16th, 2021 09:59 DELAYED |
| BID | 7.95 | ASK | 8.15 | ||
| Open | 8.12 | Previous Close | 7.95 | ||
| Pre-Market | - | After-Market | - | ||
| - -% | - - |
| Target Price | 13.00 | Analyst Rating | Strong Buy 1.25 | |
| Potential % | 63.52 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/100 | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/100 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/100 | Income Ranking | — - | |
| Market Cap | 386.05M | Earnings Rating | Strong Buy | |
| Price Range Ratio 52W % | 46.82 | Earnings Date | 6th May 2021 |
Today's Price Range 7.828.18 | 52W Range 5.1011.38 | 5 Year PE Ratio Range -2.80-4.40 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 3.11% | ||
| 1 Month | 3.79% | ||
| 3 Months | -0.38% | ||
| 6 Months | -2.57% | ||
| 1 Year | 47.76% | ||
| 3 Years | -11.76% | ||
| 5 Years | -20.18% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -84.25 | |||
ROE last 12 Months | -80.93 | |||
ROA (5Y Avg) | -41.25 | |||
ROA last 12 Months | -66.09 | |||
ROC (5Y Avg) | -86.46 | |||
ROC last 12 Months | -71.21 | |||
Return on invested Capital Q | -15.87 | |||
Return on invested Capital Y | -77.45 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -4.80 | ||||
| 2.64 | ||||
| - | ||||
| - | ||||
| -6.50 | ||||
| -1.42 | ||||
| 2.64 | ||||
| 2.91 | ||||
| 227.94M | ||||
| Forward PE | -7.07 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 8.90 | ||||
| 9.10 | ||||
| 0.04 | ||||
| 0.04 | ||||
| - | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| -691.80 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -0.29 | -0.34 | -17.24 |
| Q03 2020 | -0.38 | -0.29 | 23.68 |
| Q02 2020 | -0.39 | -0.40 | -2.56 |
| Q01 2020 | -0.65 | -0.57 | 12.31 |
| Q04 2019 | -0.71 | -0.65 | 8.45 |
| Q03 2019 | -0.56 | -0.66 | -17.86 |
| Q02 2019 | -0.50 | -0.55 | -10.00 |
| Q01 2019 | -0.50 | -0.59 | -18.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2021 QR | -0.13 | 58.06 | Positive |
| 6/2021 QR | -0.37 | -12.12 | Negative |
| 12/2021 FY | -1.29 | -0.78 | Negative |
| 12/2022 FY | -1.09 | 31.88 | Positive |
| Next Report Date | 6th May 2021 |
| Estimated EPS Next Report | -0.13 |
| Estimates Count | 3 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 33.10K |
| Shares Outstanding | 48.02M |
| Trades Count | 278 |
| Dollar Volume | 2.11M |
| Avg. Volume | 209.83K |
| Avg. Weekly Volume | 76.16K |
| Avg. Monthly Volume | 154.95K |
| Avg. Quarterly Volume | 210.44K |
Aeglea BioTherapeutics Inc. (NASDAQ: AGLE) stock closed at 7.95 per share at the end of the most recent trading day (a 5.3% change compared to the prior day closing price) with a volume of 119.76K shares and market capitalization of 386.05M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 87 people. Aeglea BioTherapeutics Inc. CEO is Anthony G. Quinn.
The one-year performance of Aeglea BioTherapeutics Inc. stock is 47.76%, while year-to-date (YTD) performance is 1.02%. AGLE stock has a five-year performance of -20.18%. Its 52-week range is between 5.1 and 11.38, which gives AGLE stock a 52-week price range ratio of 46.82%
Aeglea BioTherapeutics Inc. currently has a PE ratio of -4.80, a price-to-book (PB) ratio of 2.64, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -66.09%, a ROC of -71.21% and a ROE of -80.93%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Aeglea BioTherapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.13 for the next earnings report. Aeglea BioTherapeutics Inc.’s next earnings report date is 06th May 2021.
The consensus rating of Wall Street analysts for Aeglea BioTherapeutics Inc. is Strong Buy (1.25), with a target price of $13, which is +63.52% compared to the current price. The earnings rating for Aeglea BioTherapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aeglea BioTherapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aeglea BioTherapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 8.23, ATR14 : 0.48, CCI20 : 12.57, Chaikin Money Flow : 0.01, MACD : 0.02, Money Flow Index : 39.09, ROC : 12.29, RSI : 61.34, STOCH (14,3) : 56.60, STOCH RSI : 1.00, UO : 45.25, Williams %R : -43.40), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aeglea BioTherapeutics Inc. in the last 12-months were: Anthony G. Quinn (Buy at a value of $783 750)
Aeglea BioTherapeutics Inc.
Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an early clinical development stage.
CEO: Anthony G. Quinn
Telephone: +1 512 942-2935
Address: 805 Las Cimas Parkway, Austin 78746, TX, US
Number of employees: 87
